American Heart Association (AHA)

The American Heart Association (AHA) funds cardiovascular medical research, educates consumers on healthy living and fosters appropriate cardiac care in an effort to reduce disability and deaths caused by cardiovascular disease and stroke. The AHA also is a key resource for the latest cardiology science through its journals and annual meeting.

New technique could help when cardiologists repair 2 leaky heart valves at once
Performing M-TEER and T-TEER on the same patient using a single guide catheter appears to be both safe and effective. Researchers shared their experience with this approach in Circulation: Cardiovascular Interventions.
Beta-blockers do not benefit heart attack patients with a normal LVEF
The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.
Winning cash for taking blood pressure meds increases compliance
About 71% of patients in the rewards group opened their blood pressure medication on 80% of days, compared with about 34% in the control group.
Drinking coffee may reduce risk of recurrent AFib
Physicians often tell AFib patients they should limit coffee consumption to protect their hearts. This new analysis, however, suggests that may not be necessary.
AI-enabled coronary plaque quantification outperforms traditional risk scores
Researchers used AI-enabled software developed by Cleerly to evaluate the CCTA results of more than 6,000 patients. The software was consistently effective, identifying patients who may face an increased risk of poor outcomes.

An FDA panel will discuss its recommendations related to Abbott's TriClip G4 transcatheter edge-to-edge repair (TEER) system for tricuspid regurgitation.

New technique could help when cardiologists repair 2 leaky heart valves at once

Performing M-TEER and T-TEER on the same patient using a single guide catheter appears to be both safe and effective. Researchers shared their experience with this approach in Circulation: Cardiovascular Interventions.

Beta-blockers do not benefit heart attack patients with a normal LVEF

The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.

Winning cash for taking blood pressure meds increases compliance

About 71% of patients in the rewards group opened their blood pressure medication on 80% of days, compared with about 34% in the control group.

Drinking coffee may reduce risk of recurrent AFib

Physicians often tell AFib patients they should limit coffee consumption to protect their hearts. This new analysis, however, suggests that may not be necessary.

AI-enabled coronary plaque quantification outperforms traditional risk scores

Researchers used AI-enabled software developed by Cleerly to evaluate the CCTA results of more than 6,000 patients. The software was consistently effective, identifying patients who may face an increased risk of poor outcomes.

Coronary calcium may predict a patient's risk of dying from noncardiac conditions

Calcium in the coronary arteries is a known cardiac risk factor. However, new data suggest it may actually tell us more about a person's overall health than researchers previously believed.

‘Unprecedented’: Single dose of new gene-editing therapy lowers cholesterol, triglycerides

First-in-human data suggest the therapy, CTX310, could be a breakthrough for patients with lipid disorders.

Confirmed: AI software from Heartflow flags high-risk coronary plaques for cardiologists

Researchers tracked data from nearly 8,000 patients evaluated with Heartflow's FDA-cleared Plaque Analysis software. Overall, the technology's Plaque Staging feature was found to provide significant value during the diagnosis and management of these patients.